摘要
目的探讨丁苯酞联合依达拉奉对血管性痴呆患者血清超氧化物歧化酶(SOD)及丙二醛(MDA)水平的影响。方法回顾性分析2015年2月至2016年9月收治的血管性痴呆患者86例,按给药方式的不同分为联合组和单一组,各43例。单一组患者给予常规临床治疗和依达拉奉治疗,联合组患者在单一组患者治疗基础上加用丁苯酞。两组患者均治疗12周。结果联合组总有效率为88.37%,明显高于单一组的58.13%(P<0.05);治疗后,两组患者认知能力和生活质量、SOD及MDA水平、血液流变学指标均改善,联合组患者简易智力状态检查量表(MMSE)和日常生活活动能力量表(ADL)评分,SOD水平及全血低切、中切、高切黏度改善程度均明显大于单一组患者(P<0.05),而痴呆程度量表(CDR)评分及MDA水平均明显低于单一组患者(P<0.05);两组不良反应发生率无明显差异(9.30%比4.65%,P>0.05)。结论丁苯酞联合依达拉奉治疗血管性痴呆能提高治疗效果,能更好地改善患者的认知能力和生活质量,降低MDA水平和激活SOD,改善血液流变学,且安全性高,值得临床推广。
Objective To investigate the effect of butylphthalide combined with edaravone on the levels of serum superoxide dismutase（SOD） and malondialdehyde（MDA） in patients with vascular dementia（VD）. Methods Totally 86 patients with VD admitted to our hospital from February 2015 to September 2016 were selected and divided into the combined group and the single group according to the different ways of drug administration,43 cases in each group. The single group was given routine clinical treatment and edaravone,on this basis,the combined group was given butylphthalide. The two groups were treated for 12 weeks. Results The total effective rate of the combined group was 88. 37%,which was significantly higher than 58. 13% of the single group（P〈0. 05）. After treatment,the scores of mini-mental state examination（MMSE） and activity of daily living（ADL）,the levels of SOD and MDA,and the hemorheological indexes were significantly improved,and the scores of MMSE and ADL,level of SOD,and improvement of the low,medium and high shear viscosities of whole blood in the combined group were significantly greater than those in the single group,while the score of clinical dementia rating（CDR） of dementia severity and level of MDA in the combined group were significantly lower than those in the single group（P〈0. 05）. There was no significant difference in the incidence rate of adverse reactions between the two groups（9. 30% vs.4. 65%,P〉0. 05）. Conclusion Butylphthalide combined with edaravone in the treatment of patients with VD can improve the therapeutic effect,improve the patients＇ cognitive ability and quality of life,reduce the level of MDA and activate the SOD,improve the hemorheology,and it has high safety,which is worthy of clinical promotion.
作者
张凡
唐彦
窦艳霞
马萍
纪光
Zhang Fan!;Tang Yan;Dou Yanxia;Ma Ping;Ji Guang(Langfang Changzheng Hospital,Langfang,Hebei,China 065000;Baoding No.2 Central Hospital,Baoding,Hebei,China 072750;School Hospital of Hebei University of Technology,Tianjin,China 300401)
出处
《中国药业》
CAS
2018年第12期83-85,共3页
China Pharmaceuticals
